Beren Therapeutics has received the US Food and Drug Administration (FDA) acceptance to review its New Drug Application (NDA) for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset Niemann-Pick disease type C (NPC).
The submission targets adult patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer that has progressed after previous endocrine-based
This partnership aims to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership programmes and facilitate the delivery of scientifically validated, partner-ready therapeutic candidates. It will combine Syngene’s
The partnership combines UNP’s AI-driven macrocycle platform with the worldwide development and commercialisation expertise of Novartis, aiming to produce next-generation treatments for previously undruggable targets. Under this agreement,
The collaboration will combine Mayo Clinic’s Platform architecture and clinical-genomic datasets with MSD’s virtual cell technologies to improve target identification, drive early development decisions, and enhance disease understanding.
The collaboration aims to expedite early-stage drug discovery focused on innovative therapeutics, using Teijin Pharma’s expertise in computer-aided drug design (CADD) and AI. Under the agreement, both companies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
